RIGEL PHARMACEUTICALS INC (RIGL) Fundamental Analysis & Valuation
NASDAQ:RIGL • US7665597024
Current stock price
25.95 USD
-0.65 (-2.44%)
At close:
26.1331 USD
+0.18 (+0.71%)
After Hours:
This RIGL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. RIGL Profitability Analysis
1.1 Basic Checks
- In the past year RIGL was profitable.
- In the past year RIGL had a positive cash flow from operations.
- In the past 5 years RIGL reported 4 times negative net income.
- The reported operating cash flow has been mixed in the past 5 years: RIGL reported negative operating cash flow in multiple years.
1.2 Ratios
- Looking at the Return On Assets, with a value of 46.72%, RIGL belongs to the top of the industry, outperforming 99.23% of the companies in the same industry.
- RIGL's Return On Equity of 96.34% is amongst the best of the industry. RIGL outperforms 99.42% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 63.44%, RIGL belongs to the top of the industry, outperforming 99.61% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 46.72% | ||
| ROE | 96.34% | ||
| ROIC | 63.44% |
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin of RIGL (40.17%) is better than 97.69% of its industry peers.
- RIGL has a Operating Margin of 42.17%. This is amongst the best in the industry. RIGL outperforms 99.04% of its industry peers.
- The Gross Margin of RIGL (93.10%) is better than 93.45% of its industry peers.
- RIGL's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 42.17% | ||
| PM (TTM) | 40.17% | ||
| GM | 93.1% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
2. RIGL Health Analysis
2.1 Basic Checks
- RIGL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- RIGL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- RIGL has an Altman-Z score of -1.76. This is a bad value and indicates that RIGL is not financially healthy and even has some risk of bankruptcy.
- RIGL's Altman-Z score of -1.76 is in line compared to the rest of the industry. RIGL outperforms 50.48% of its industry peers.
- RIGL has a debt to FCF ratio of 0.88. This is a very positive value and a sign of high solvency as it would only need 0.88 years to pay back of all of its debts.
- Looking at the Debt to FCF ratio, with a value of 0.88, RIGL belongs to the top of the industry, outperforming 94.80% of the companies in the same industry.
- A Debt/Equity ratio of 0.25 indicates that RIGL is not too dependend on debt financing.
- With a Debt to Equity ratio value of 0.25, RIGL is not doing good in the industry: 65.70% of the companies in the same industry are doing better.
- Even though the debt/equity ratio score it not favorable for RIGL, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 0.88 | ||
| Altman-Z | -1.76 |
ROIC/WACC6.87
WACC9.24%
2.3 Liquidity
- A Current Ratio of 2.28 indicates that RIGL has no problem at all paying its short term obligations.
- RIGL has a worse Current ratio (2.28) than 73.60% of its industry peers.
- A Quick Ratio of 2.14 indicates that RIGL has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 2.14, RIGL is doing worse than 73.41% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.14 |
3. RIGL Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 593.62% over the past year.
EPS 1Y (TTM)593.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%21.19%
3.2 Future
- Based on estimates for the next years, RIGL will show a decrease in Earnings Per Share. The EPS will decrease by -2.44% on average per year.
- The Revenue is expected to grow by 6.25% on average over the next years.
EPS Next Y-36.48%
EPS Next 2Y-13.06%
EPS Next 3Y-8.59%
EPS Next 5Y-2.44%
Revenue Next Year-3.44%
Revenue Next 2Y4.1%
Revenue Next 3Y9.65%
Revenue Next 5Y6.25%
3.3 Evolution
4. RIGL Valuation Analysis
4.1 Price/Earnings Ratio
- RIGL is valuated cheaply with a Price/Earnings ratio of 3.98.
- Compared to the rest of the industry, the Price/Earnings ratio of RIGL indicates a rather cheap valuation: RIGL is cheaper than 99.42% of the companies listed in the same industry.
- When comparing the Price/Earnings ratio of RIGL to the average of the S&P500 Index (25.70), we can say RIGL is valued rather cheaply.
- RIGL is valuated cheaply with a Price/Forward Earnings ratio of 6.27.
- 98.46% of the companies in the same industry are more expensive than RIGL, based on the Price/Forward Earnings ratio.
- RIGL's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.84.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.98 | ||
| Fwd PE | 6.27 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, RIGL is valued cheaply inside the industry as 99.23% of the companies are valued more expensively.
- Based on the Price/Free Cash Flow ratio, RIGL is valued cheaper than 98.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.91 | ||
| EV/EBITDA | 2.61 |
4.3 Compensation for Growth
- The decent profitability rating of RIGL may justify a higher PE ratio.
- RIGL's earnings are expected to decrease with -8.59% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.06%
EPS Next 3Y-8.59%
5. RIGL Dividend Analysis
5.1 Amount
- RIGL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
RIGL Fundamentals: All Metrics, Ratios and Statistics
25.95
-0.65 (-2.44%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-03 2026-03-03/amc
Earnings (Next)05-04 2026-05-04
Inst Owners91.09%
Inst Owner Change6.53%
Ins Owners3.09%
Ins Owner Change6.76%
Market Cap470.99M
Revenue(TTM)N/A
Net Income(TTM)113.30M
Analysts80
Price Target47.94 (84.74%)
Short Float %21.57%
Short Ratio9.16
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.05%
Min EPS beat(2)24.64%
Max EPS beat(2)67.46%
EPS beat(4)4
Avg EPS beat(4)188.12%
Min EPS beat(4)24.64%
Max EPS beat(4)592.43%
EPS beat(8)7
Avg EPS beat(8)242.36%
EPS beat(12)11
Avg EPS beat(12)181.29%
EPS beat(16)14
Avg EPS beat(16)138.58%
Revenue beat(2)2
Avg Revenue beat(2)11.07%
Min Revenue beat(2)10.05%
Max Revenue beat(2)12.08%
Revenue beat(4)4
Avg Revenue beat(4)12.62%
Min Revenue beat(4)9.15%
Max Revenue beat(4)19.17%
Revenue beat(8)7
Avg Revenue beat(8)10.41%
Revenue beat(12)11
Avg Revenue beat(12)14.43%
Revenue beat(16)12
Avg Revenue beat(16)11.18%
PT rev (1m)0%
PT rev (3m)3.68%
EPS NQ rev (1m)7.09%
EPS NQ rev (3m)17.09%
EPS NY rev (1m)0.23%
EPS NY rev (3m)1.14%
Revenue NQ rev (1m)1.14%
Revenue NQ rev (3m)3.4%
Revenue NY rev (1m)0.27%
Revenue NY rev (3m)0.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.98 | ||
| Fwd PE | 6.27 | ||
| P/S | 1.67 | ||
| P/FCF | 6.91 | ||
| P/OCF | 6.91 | ||
| P/B | 4 | ||
| P/tB | 5.1 | ||
| EV/EBITDA | 2.61 |
EPS(TTM)6.52
EY25.13%
EPS(NY)4.14
Fwd EY15.96%
FCF(TTM)3.75
FCFY14.47%
OCF(TTM)3.76
OCFY14.48%
SpS15.54
BVpS6.48
TBVpS5.08
PEG (NY)N/A
PEG (5Y)N/A
Graham Number30.83
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 46.72% | ||
| ROE | 96.34% | ||
| ROCE | 80.3% | ||
| ROIC | 63.44% | ||
| ROICexc | 854.98% | ||
| ROICexgc | N/A | ||
| OM | 42.17% | ||
| PM (TTM) | 40.17% | ||
| GM | 93.1% | ||
| FCFM | 24.16% |
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
F-Score7
Asset Turnover1.16
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 0.88 | ||
| Debt/EBITDA | 0.25 | ||
| Cap/Depr | 1.57% | ||
| Cap/Sales | 0.01% | ||
| Interest Coverage | 17.61 | ||
| Cash Conversion | 56.17% | ||
| Profit Quality | 60.14% | ||
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.14 | ||
| Altman-Z | -1.76 |
F-Score7
WACC9.24%
ROIC/WACC6.87
Cap/Depr(3y)424.8%
Cap/Depr(5y)301.24%
Cap/Sales(3y)4.48%
Cap/Sales(5y)3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)593.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.75%
EPS Next Y-36.48%
EPS Next 2Y-13.06%
EPS Next 3Y-8.59%
EPS Next 5Y-2.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%21.19%
Revenue Next Year-3.44%
Revenue Next 2Y4.1%
Revenue Next 3Y9.65%
Revenue Next 5Y6.25%
EBIT growth 1Y1151.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year546.96%
EBIT Next 3Y91.91%
EBIT Next 5Y95.89%
FCF growth 1Y286.79%
FCF growth 3Y80.89%
FCF growth 5YN/A
OCF growth 1Y418.44%
OCF growth 3Y74.92%
OCF growth 5YN/A
RIGEL PHARMACEUTICALS INC / RIGL Fundamental Analysis FAQ
What is the ChartMill fundamental rating of RIGEL PHARMACEUTICALS INC (RIGL) stock?
ChartMill assigns a fundamental rating of 5 / 10 to RIGL.
What is the valuation status for RIGL stock?
ChartMill assigns a valuation rating of 8 / 10 to RIGEL PHARMACEUTICALS INC (RIGL). This can be considered as Undervalued.
Can you provide the profitability details for RIGEL PHARMACEUTICALS INC?
RIGEL PHARMACEUTICALS INC (RIGL) has a profitability rating of 6 / 10.
How financially healthy is RIGEL PHARMACEUTICALS INC?
The financial health rating of RIGEL PHARMACEUTICALS INC (RIGL) is 6 / 10.